ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
32 announcements
Promoter Saurabh Goyal acquired shares of Nureca Limited on the open market for a total consideration of ₹0.09 Crore, complying with SEBI PIT regulations.
Nureca Limited's promoter, Saurabh Goyal, acquired 26,996 shares through multiple open market transactions between September 10 and September 22, 2026. This increased his holding from 69.62% to 69.91%.
Smita Goyal, a promoter-group member of Nureca Ltd, bought 57,337 shares in the open market. Her stake rose to 0.60% of the company's equity.
Nureca promoter group member Smita Goyal purchased 1,050 shares worth ₹0.03 Crore on NSE and BSE. Her stake rose from 0.58% to 0.59%.
Promoter group member Smita Goyal purchased shares on the open market worth ₹0.33 Crore. This disclosure complies with SEBI PIT regulations.
Nureca Limited settled a GST matter by reversing Input Tax Credit of Rs. 15,40,311. Following rectification, the authorities dropped the related tax demand for the 2021-22 period.
Smita Goyal (Promoter Group) purchased shares via open market for ₹1.41 Crore. This disclosure follows Regulation 7(2) of PIT Regulations due to a system-driven reporting delay.
Nureca Limited settled a GST dispute for the 2021-22 period following a Final Order of Rectification. The matter concluded with an Input Tax Credit reversal of Rs. 0.15 Crore.
Nureca Limited announced the re-appointment of Saurabh Goyal as Managing Director and the appointment of Smita Goyal as Whole-time Director, effective September and June 2026.
Nureca Limited held its 10th Annual General Meeting on July 28, 2026. Shareholders adopted financial statements and approved the reappointment of directors and the Managing Director.
Nureca Limited reported its strongest performance in 16 quarters for Q1 FY'27, achieving a revenue of ₹40.3 Cr and shifting to a profitable trajectory with a 10.5% PBT margin.
Nureca Ltd reported revenue from operations of ₹40.3 Cr (+17.8% YoY) and net profit of ₹3.1 Cr (+287.5% YoY) for Q1 FY27.
Nureca Ltd filed its quarterly shareholding pattern under Regulation 31(1)(b) for the period ending June 30, 2026.
Nureca Limited scheduled a board meeting on July 21, 2026. The board will consider and approve unaudited financial results for the June quarter.
Nureca Limited scheduled its 10th Annual General Meeting for July 28, 2026 via video conference. Agenda includes adopting financial statements and re-appointing key directors.
Nureca Ltd filed its Annual Report for FY25-26, highlighting a turnaround with ₹8.5 Cr operating profit. The AGM is scheduled for July 28, 2026.
Promoter group member Payal Goyal disposed of 20,59,928 equity shares via an off-market family settlement. The transaction, disclosed as an abundant precaution, reduces her holding to zero.
Nureca promoter Saurabh Goyal acquired shares via off-market family settlement. The transaction increased his stake to 68.09%, as disclosed to exchanges.
Aryan Goyal resigned as Executive Director and CEO effective July 1, 2026. This follows a family settlement involving the transfer of his shareholding to Saurabh Goyal.
Saurabh Goyal, a promoter of Nureca Limited, will acquire 32,19,113 shares via inter-se transfer. This 33.74% stake re-alignment within the promoter group is valued at Rs.80.65 Crore.
Nureca Limited promoters completed an inter-se transfer of 60,842 equity shares. Total promoter group holding remains unchanged at 68.09% following this off-market realignment.
Nureca Ltd promoter group entity Nectar Biopharma sold its entire 0.63% stake (60,842 shares) for ₹1.44 Crore. The transaction was executed off-market on June 9, 2026.
Promoter Mr. Saurabh Goyal acquired 60,842 shares of Nureca Limited for ₹1.44 Crore through an off-market transaction. This purchase increases his total shareholding to 34.35%.
Nureca Limited issued a corrigendum to its May 29 board meeting outcome. The board-approved incremental capex for plant and machinery was corrected to ₹128 Crore.
Nureca Limited announced a leadership overhaul including a new CFO and Executive Director. These changes aim to ensure operational continuity and strengthen strategic management oversight.
Nureca Limited updated its authorized personnel list for materiality disclosures under SEBI Regulation 30(5). Mr. Chander Kant will succeed Mr. Naresh Gupta as CFO effective June 27, 2026.
Nureca Limited achieved a significant operational turnaround in FY26, posting an operating profit of ₹8.5 Cr versus a ₹7.5 Cr loss in FY25, despite a Q4 FY26 net loss due to investment fair value changes.
Nureca Ltd reported revenue from operations of ₹35.4 Cr (+11.7% YoY) and a net loss of ₹6.1 Cr for Q4 FY26.
Nureca Limited approved FY26 financial results and a ₹100 Crore incremental capex for medical device manufacturing. The board also appointed Chander Kant as CFO.
Nureca Limited deposited ₹0.57 Crore with the DRI following a product classification hearing. No formal order has been issued, and the deposit implies no liability.